Clinigen Group
Market Cap
UK£1.1b
Last Updated
2019/10/17 21:10 UTC
Data Sources
Company Financials +
Executive Summary
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally.
Snowflake
Fundamentals
High growth potential and slightly overvalued.
Similar Companies
Share Price & News
How has Clinigen Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-1.6%
CLIN
2.4%
GB Life Sciences
1.7%
GB Market
1 Year Return
-5.2%
CLIN
-0.5%
GB Life Sciences
2.9%
GB Market
Return vs Industry: CLIN underperformed the UK Life Sciences industry which returned -0.5% over the past year.
Return vs Market: CLIN underperformed the UK Market which returned 2.9% over the past year.
Shareholder returns
| CLIN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.6% | 2.4% | 1.7% |
| 30 Day | -8.4% | -5.9% | -0.7% |
| 90 Day | -13.7% | -7.3% | -1.8% |
| 1 Year | -4.6%-5.2% | -0.2%-0.5% | 8.0%2.9% |
| 3 Year | 11.1%9.3% | 14.4%13.4% | 18.2%3.8% |
| 5 Year | 85.7%81.1% | 28.5%26.9% | 35.6%6.1% |
Price Volatility Vs. Market
How volatile is Clinigen Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
The Clinigen Group (LON:CLIN) Share Price Is Up 100% And Shareholders Are Holding On1 month ago | Simply Wall St
Is Clinigen Group (LON:CLIN) A Risky Investment?1 month ago | Simply Wall St
Should You Worry About Clinigen Group Plc's (LON:CLIN) CEO Pay?Valuation
Is Clinigen Group undervalued compared to its fair value and its price relative to the market?
38.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: CLIN (£8.2) is trading below our estimate of fair value (£13.24)
Significantly Undervalued: CLIN is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CLIN is poor value based on its PE Ratio (204.7x) compared to the Life Sciences industry average (39.7x).
PE vs Market: CLIN is poor value based on its PE Ratio (204.7x) compared to the UK market (16.7x).
Price to Earnings Growth Ratio
Low PEG Ratio: CLIN is poor value based on its PEG Ratio (6x)
Price to Book Ratio
PB vs Industry: CLIN is good value based on its PB Ratio (2.5x) compared to the GB Life Sciences industry average (2.7x).
Next Steps
Future Growth
How is Clinigen Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
33.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLIN's forecast earnings growth (33.9% per year) is above the savings rate (1.2%).
Earnings vs Market: CLIN's earnings (33.9% per year) are forecast to grow faster than the UK market (12.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CLIN's revenue (9% per year) is forecast to grow faster than the UK market (3.9% per year).
High Growth Revenue: CLIN's revenue (9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: CLIN's Return on Equity is forecast to be high in 3 years time (20.1%)
Next Steps
Past Performance
How has Clinigen Group performed over the past 5 years?
12.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: CLIN's earnings have grown by 12.4% per year over the past 5 years.
Accelerating Growth: CLIN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CLIN had negative earnings growth (-81%) over the past year, making it difficult to compare to the Life Sciences industry average (14%).
Return on Equity
High ROE: CLIN's Return on Equity (1.2%) is considered low.
Return on Assets
ROA vs Industry: CLIN's Return on Assets is below or equal to the Life Sciences industry average last year.
Return on Capital Employed
ROCE Improving: CLIN's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Clinigen Group's financial position?
Financial Position Analysis
Short Term Liabilities: CLIN's short term assets (£231.3M) do not cover its short term liabilities (£243.4M)
Long Term Liabilities: CLIN's short term assets (231.3M) do not cover its long term liabilities (384.3M)
Debt to Equity History and Analysis
Debt Level: CLIN's debt to equity ratio (76.6%) is considered high
Reducing Debt: CLIN's debt to equity ratio has increased from 24.6% to 76.6% over the past 5 years.
Debt Coverage: CLIN's debt is well covered by operating cash flow (20.3%).
Interest Coverage: CLIN's interest payments on its debt are well covered by EBIT (6.7x coverage).
Balance Sheet
Inventory Level: CLIN has a low level of unsold assets or inventory.
Debt Coverage by Assets: CLIN's debt is not covered by short term assets (assets are 0.7x debt).
Next Steps
Dividend
What is Clinigen Group's current dividend yield, its reliability and sustainability?
0.82%
Current Dividend Yield
Upcoming Dividend Payment
Purchase Clinigen Group before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: CLIN's dividend (0.82%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.99%).
High Dividend: CLIN's dividend (0.82%) is low compared to the top 25% of dividend payers in the UK market (5.41%).
Stable Dividend: CLIN is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.
Growing Dividend: CLIN is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CLIN is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CLIN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
What is the CEO of Clinigen Group's salary, the management and board of directors tenure and is there insider trading?
2.9yrs
Average management tenure
CEO
Shaun Chilton (51yo)
2.9yrs
Tenure
UK£2,558,000
Compensation
Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016. Mr. Edward served as Group Deputy Chief Executive Officer of Clinigen Group Plc since July 22, 2 ...
CEO Compensation Analysis
Compensation vs. Market: Shaun's total compensation ($USD3.29M) is about average for companies of similar size in the UK market ($USD1.81M).
Compensation vs Earnings: Shaun's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Management Age and Tenure
2.9yrs
Average Tenure
51yo
Average Age
Experienced Management: CLIN's management team is considered experienced (2.9 years average tenure).
Board Age and Tenure
4.0yrs
Average Tenure
59yo
Average Age
Experienced Board: CLIN's board of directors are considered experienced (4 years average tenure).
Insider Trading
Insider Buying: CLIN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors CFO & Executive Director |
| Shares | 3,900 |
| Max Price | UK£8.93 |
Ownership Breakdown
Management Team
Shaun Chilton (51yo)
CEO & Executive Director
- Tenure: 2.9yrs
- Compensation: UK£2.56m
Ivo Timmermans (59yo)
Chief Medial Officer
- Tenure: 3.7yrs
Nick Keher
CFO & Executive Director
- Tenure: 0.6yrs
- Compensation: UK£347.27k
Mark Corbett
Managing Director of Global Access Division
- Tenure: 6.3yrs
David Bryant
Director of Corporate Development
- Tenure: 5.3yrs
Johannes Willemse (51yo)
Chief Commercial Officer
- Tenure: 0yrs
Debra Ainge
Chief Operating Officer
- Tenure: 0yrs
Jessica Archer
Global Human Resources Director
- Tenure: 2.9yrs
Matt Parrish
Head of Investor Relations
- Tenure: 0yrs
Amanda Miller
General Counsel & Company Secretary
- Tenure: 2.3yrs
Board Members
Ian Nicholson (59yo)
Independent Non-Executive Director
- Tenure: 7.1yrs
- Compensation: UK£70.00k
Peter Allen (63yo)
Independent Non-Executive Chairman
- Tenure: 7.2yrs
- Compensation: UK£143.00k
Alan Boyd (64yo)
Non-Executive Director
- Tenure: 0.9yrs
- Compensation: UK£39.00k
Anne Hyland (58yo)
Independent Non-Executive Director
- Tenure: 1.8yrs
- Compensation: UK£70.00k
Shaun Chilton (51yo)
CEO & Executive Director
- Tenure: 2.9yrs
- Compensation: UK£2.56m
Nick Keher
CFO & Executive Director
- Tenure: 0.6yrs
- Compensation: UK£347.27k
John Hartup (68yo)
Senior Independent Non-Executive Director
- Tenure: 0yrs
- Compensation: UK£70.00k
Johannes Willemse (51yo)
Chief Commercial Officer
- Tenure: 0yrs
Company Information
Clinigen Group plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Clinigen Group plc
- Ticker: CLIN
- Exchange: AIM
- Founded: 2008
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£1.094b
- Shares outstanding: 132.84m
- Website: https://www.clinigengroup.com
Number of Employees
Location
- Clinigen Group plc
- Pitcairn House
- Crown Square
- Burton-on-Trent
- Staffordshire
- DE14 2WW
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CLIN | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Sep 2012 |
| CLIG.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Sep 2012 |
| 78C | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Sep 2012 |
Biography
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segmen ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 21:10 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.